NCT00792948 2026-03-18
Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
95 trialsNCT03418038 2026-03-18
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Mayo Clinic
Phase 2 Recruiting
NCT03914625 2026-03-18
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT06207123 2026-03-18
A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)
University of Chicago
Phase 1/2 Recruiting
NCT06317662 2026-03-18
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06918431 2026-03-17
Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
City of Hope Medical Center
Phase 2 Recruiting
NCT06289673 2026-03-03
Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
St. Jude Children's Research Hospital
Phase 4 Recruiting
NCT03007147 2026-02-23
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Children's Oncology Group
Phase 3 Active not recruiting
NCT03136146 2026-02-17
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06533748 2026-02-12
Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma
St. Jude Children's Research Hospital
Phase 2 Recruiting
NCT03020030 2026-01-22
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents
Dana-Farber Cancer Institute
Phase 3 Active not recruiting
NCT03808610 2026-01-09
Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT00501826 2026-01-07
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT02553460 2025-12-10
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I
St. Jude Children's Research Hospital
Phase 1/2 Active not recruiting
NCT01424982 2025-12-05
Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03117751 2025-12-05
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
St. Jude Children's Research Hospital
Phase 2/3 Active not recruiting
NCT02112916 2025-12-01
Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT02003222 2025-11-28
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT07227584 2025-11-12
ALL Backbone in AYAs
Dana-Farber Cancer Institute
Phase 2 Not yet recruiting
NCT02877303 2025-11-06
Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03132454 2025-11-03
Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT05645718 2025-10-07
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05192889 2025-09-22
Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax
St. Jude Children's Research Hospital
Phase 1/2 Active not recruiting
NCT05032183 2025-08-11
Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT03805932 2025-07-24
Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia
National Institutes of Health Clinical Center (CC)
Phase 1 Active not recruiting
NCT04752163 2025-05-23
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT03576547 2025-05-08
Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT00408005 2025-04-20
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
National Cancer Institute (NCI)
Phase 3 Completed
NCT02828358 2025-02-27
Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement
National Cancer Institute (NCI)
Phase 2 Completed
NCT00390793 2025-02-17
Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04996160 2025-01-24
Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (RELPALL2)
Stanford University
Phase 1 Recruiting
NCT05476770 2024-12-06
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1 Recruiting
NCT00557193 2024-07-15
Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Children's Oncology Group
Phase 3 Completed
NCT06210750 2024-05-17
Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT01626664 2024-04-25
KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)
Kyowa Kirin Co., Ltd.
Phase 2 Completed
NCT00381680 2024-03-26
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Children's Oncology Group
Phase 3 Completed
NCT02135874 2024-03-22
Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02547662 2023-10-30
Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia
Mayo Clinic
Phase 2 Completed
NCT00005585 2023-04-06
Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia
Children's Oncology Group
Phase 3 Completed
NCT00783367 2023-03-30
Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT03121534 2023-02-17
Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01005914 2023-01-06
Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT03349281 2022-10-20
Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL
University of Miami
Phase 1 Completed
NCT01319981 2022-09-27
Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01451515 2022-06-28
NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma
St. Jude Children's Research Hospital
Phase 2 Completed
NCT02293109 2022-03-10
Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma
University of California, Davis
Phase 1 Completed
NCT02464657 2021-10-07
Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01381692 2021-10-04
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00103285 2021-06-14
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Children's Oncology Group
Phase 3 Completed
NCT01363128 2021-05-03
Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
M.D. Anderson Cancer Center
Phase 2 Completed